- Home
- QURE
QURE
uniQure N.V.
as of 03-27-2026 4:00pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | 248 | City: | AMSTERDAM |
| Market Cap: | 663.4M | IPO Year: | 2013 |
| Target Price: | $44.92 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.46 | EPS Growth: | 29.67 |
| 52 Week Low/High: | $7.76 - $71.50 | Next Earning Date: | 03-02-2026 |
| Revenue: | $13,107,000 | Revenue Growth: | -47.78% |
| Revenue Growth (this year): | 126.12% | Revenue Growth (next year): | 210.54% |
| P/E Ratio: | -4.51 | Index: | N/A |
| Free Cash Flow: | -178402000.0 | FCF Growth: | N/A |
AI-Powered QURE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of uniQure N.V. (QURE)
Chief Medical Officer
Avg Cost/Share
$9.06
Shares
808
Total Value
$7,320.48
Owned After
189,669
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$9.06
Shares
3,412
Total Value
$30,912.72
Owned After
138,483
SEC Form 4
CEO, Managing Director
Avg Cost/Share
$9.06
Shares
14,581
Total Value
$132,103.86
Owned After
660,658
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$9.06
Shares
12,000
Total Value
$108,720.00
Owned After
226,581
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$9.95
Shares
1,660
Total Value
$16,517.00
Owned After
189,669
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$9.95
Shares
8,578
Total Value
$85,351.10
Owned After
138,483
SEC Form 4
CEO, Managing Director
Avg Cost/Share
$9.95
Shares
34,437
Total Value
$342,648.15
Owned After
660,658
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$9.95
Shares
12,532
Total Value
$124,693.40
Owned After
226,581
SEC Form 4
CEO, Managing Director
Avg Cost/Share
$23.86
Shares
12,378
Total Value
$295,339.08
Owned After
660,658
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$23.86
Shares
6,217
Total Value
$148,337.62
Owned After
226,581
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | QURE | Chief Medical Officer | Mar 4, 2026 | Sell | $9.06 | 808 | $7,320.48 | 189,669 | |
| Potts Jeannette | QURE | Chief Legal Officer | Mar 4, 2026 | Sell | $9.06 | 3,412 | $30,912.72 | 138,483 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Mar 4, 2026 | Sell | $9.06 | 14,581 | $132,103.86 | 660,658 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Mar 4, 2026 | Sell | $9.06 | 12,000 | $108,720.00 | 226,581 | |
| Abi-Saab Walid | QURE | Chief Medical Officer | Mar 2, 2026 | Sell | $9.95 | 1,660 | $16,517.00 | 189,669 | |
| Potts Jeannette | QURE | Chief Legal Officer | Mar 2, 2026 | Sell | $9.95 | 8,578 | $85,351.10 | 138,483 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Mar 2, 2026 | Sell | $9.95 | 34,437 | $342,648.15 | 660,658 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Mar 2, 2026 | Sell | $9.95 | 12,532 | $124,693.40 | 226,581 | |
| Kapusta Matthew C | QURE | CEO, Managing Director | Feb 25, 2026 | Sell | $23.86 | 12,378 | $295,339.08 | 660,658 | |
| KLEMT CHRISTIAN | QURE | Chief Financial Officer | Feb 25, 2026 | Sell | $23.86 | 6,217 | $148,337.62 | 226,581 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 2, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYMar 2, 2026 · 100% conf.
1D
+8.50%
$11.53
Act: -15.05%
5D
+8.06%
$11.49
Act: +67.83%
20D
+4.47%
$11.10
uniQure N.V._March 2, 2026 000159056000-0000000false00015905602026-03-022026-03-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 uniQure N.V. (Exact Name of Registrant as Specified in Charter) The Netherlands 001-36294 N/A
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands N/A
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: +31-20-240-6000 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class: Trading Symbol(s) Name of each exchange on which registered:
Ordinary Shares, par value €0.05 per share
QURE
The Nasdaq Stock Market LLC The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 2, 2026, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 7.01 Regulation FD Disclosure. On March 2, 2026, the Company issued a press release announcing a regulatory update on AMT-130, the Company’s investigational gene therapy for Huntington’s disease. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No. Description
99.1 Press Release of uniQure N.V. regarding its financial results dated March 2, 2026
99.2 Press Release of uniQure N.V. regarding a regulatory update dated March 2, 2026
104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNIQURE N.V.
Date: March 2, 2026 By: /s/ JEANNETTE POTTS
Jeannette Potts
Chief Legal and Compliance Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
uniQure N.V._November 10, 2025 000159056000-0000000false00015905602025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 uniQure N.V. (Exact Name of Registrant as Specified in Charter) The Netherlands
001-36294
N/A
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands
N/A
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: +31-20-240-6000 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s)
Name of each exchange on which registered:
Ordinary Shares, par value €0.05 per share
QURE
The Nasdaq Stock Market LLC The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2025, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1 Press Release of uniQure N.V. dated November 10, 2025
104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNIQURE N.V.
Date: November 10, 2025 By: /s/ JEANNETTE POTTS
Jeannette Potts
Chief Legal and Compliance Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 29, 2025
Q2 2025 Earnings
8-KJul 29, 2025
000159056000-0000000false00015905602025-07-292025-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 uniQure N.V. (Exact Name of Registrant as Specified in Charter) The Netherlands
001-36294
N/A
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands
N/A
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: +31-20-240-6000 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s)
Name of each exchange on which registered:
Ordinary Shares, par value €0.05 per share
QURE
The Nasdaq Stock Market LLC The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On July 29, 2025, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and highlighting Company progress. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1 Press Release of uniQure N.V. dated July 29, 2025
104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UNIQURE N.V.
Date: July 29, 2025 By: /s/ JEANNETTE POTTS
Jeannette Potts
Chief Legal and Compliance Officer
Compare QURE vs Leading Stocks
See how QURE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.